Buprenorphine for opioid use disorders during pregnancy a review of comparative clinical effectiveness, safety, cost-effectiveness, and guidelines
The purpose of this report is to review and appraise the evidence for the clinical effectiveness, safety, and cost-effectiveness of various buprenorphine monoproducts and buprenorphine-naloxone combination formulations for UOD during pregnancy. Additionally, this report aims to review current eviden...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
May 9, 2019, 2019
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The purpose of this report is to review and appraise the evidence for the clinical effectiveness, safety, and cost-effectiveness of various buprenorphine monoproducts and buprenorphine-naloxone combination formulations for UOD during pregnancy. Additionally, this report aims to review current evidence-based guidelines regarding appropriate buprenorphine formulation use for this population |
|---|---|
| Physical Description: | 1 PDF file (18 pages) illustrations |